- Home
- PPSI vs RFL Comparison
PPSI vs RFL Comparison
Compare PPSI & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PPSI | RFL |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Real Estate |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.8M | 61.1M |
| IPO Year | 2008 | 2017 |
Fundamental Metrics
Financial Performance| Metric | PPSI | RFL |
|---|---|---|
| Price | $3.33 | $1.48 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 74.9K | ★ 88.6K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1626.32 | 28.28 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $22,879,000.00 | $917,000.00 |
| Revenue This Year | $26.84 | N/A |
| Revenue Next Year | $10.26 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $2.26 | $1.12 |
| 52 Week High | $5.70 | $3.19 |
Technical Indicators
Market Signals| Indicator | PPSI | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 35.02 | 66.76 |
| Support Level | $3.25 | $1.41 |
| Resistance Level | $4.05 | $1.63 |
| Average True Range (ATR) | 0.22 | 0.11 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 9.27 | 75.10 |
Price Performance
Historical ComparisonAbout PPSI Pioneer Power Solutions Inc.
Pioneer Power Solutions Inc designs, manufactures, integrates, services, and sells distributed energy resources, on-site and mobile power generation equipment, and a platform of mobile electric vehicle (EV) charging solutions.. Its principal products and services include custom-engineered electrical transformers, switchgear and engine-generator sets and controls, complemented by a national field-service network to maintain and repair power generation assets.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.